Pegylated liposomal doxorubicin in the treatment of cancers of the breast and ovary

Peglyated liposomal doxorubicin was developed to maintain or enhance the demonstrated antineoplastic effects of doxorubicin, while improving the toxicity profile associated with this important cytotoxic agent. Accumulating clinical data have confirmed the activity of pegylated liposomal doxorubicin in cancers of the breast and ovary. Furthermore, Phase II and III trial experience has revealed that the drug produces objective responses comparable in rate and duration to doxorubicin and other single agents employed in metastatic breast cancer. In recurrent and platinum-resistant ovarian cancer, single-agent pegylated liposomal doxorubicin has assumed an important role in routine patient management.

[1]  E. Nagore,et al.  Antineoplastic Therapy—Induced Palmar Plantar Erythrodysesthesia (‘Hand-Foot’) Syndrome , 2000, American journal of clinical dermatology.

[2]  A. Santoro,et al.  Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  A. Neugut,et al.  Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  F. Caponigro,et al.  Phase I study of Caelyx (doxorubicin HCL, pegylated liposomal) in recurrent or metastatic head and neck cancer. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  R. Berkowitz,et al.  The clinical utility of liposomal doxorubicin in recurrent ovarian cancer. , 2001, Gynecologic oncology.

[6]  K. Gelmon,et al.  Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. , 2005, The Lancet. Oncology.

[7]  S. Swain,et al.  Congestive heart failure in patients treated with doxorubicin , 2003, Cancer.

[8]  M. Markman,et al.  Cardiac safety profile of prolonged (>or=6 cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignancies. , 2004, Gynecologic oncology.

[9]  F. Muggia,et al.  Liposomal anthracycline treatment for ovarian cancer. , 2004, Seminars in oncology.

[10]  D. Alberts,et al.  Role of pegylated liposomal doxorubicin in ovarian cancer. , 2005, Gynecologic oncology.

[11]  K. Gelmon,et al.  A multi-centre phase II trial of pegylated liposomal doxorubicin and trastuzumab in HER-2 over-expressing metastatic breast cancer (MBC) , 2004 .

[12]  L J Liang,et al.  Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  K. Tolba,et al.  Cardiotoxicity of cancer therapy. , 1999, Cancer investigation.

[14]  A. Howell,et al.  Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  G. Hortobagyi,et al.  Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  S. Groshen,et al.  Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin , 2001, Cancer.

[17]  R. Bast,et al.  Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  D. Chi,et al.  The costs and efficacy of liposomal doxorubicin in platinum-refractory ovarian cancer in heavily pretreated patients. , 2001, Gynecologic oncology.

[19]  Maurie Markman,et al.  Skin toxicity associated with pegylated liposomal doxorubicin (40 mg/m2) in the treatment of gynecologic cancers. , 2005, Gynecologic oncology.

[20]  P. Rose,et al.  Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages. , 2001, Gynecologic oncology.

[21]  E. Winer,et al.  The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer. , 2004, Seminars in oncology.

[22]  D Guthrie,et al.  Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  D. Tzemach,et al.  Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes , 1999, Cancer.

[24]  J. Hainsworth,et al.  Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  E. Winer,et al.  Phase I study of Doxil and vinorelbine in metastatic breast cancer. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  M. Runge,et al.  Doxorubicin-Induced Cardiomyopathy , 2000 .

[27]  D. Spriggs,et al.  Anthracyclines in the treatment of gynecologic malignancies. , 2002, Gynecologic oncology.

[28]  D. Tzemach,et al.  Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma , 2000, Cancer.

[29]  D. Northfelt,et al.  Lack of vesicant injury following extravasation of liposomal doxorubicin. , 1995, Journal of the National Cancer Institute.

[30]  D. Alberts,et al.  Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. , 2004, Seminars in oncology.

[31]  V. Georgoulias,et al.  Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  F M Muggia,et al.  Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  M. Markman,et al.  Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. , 2000, Gynecologic oncology.

[34]  Steven Sun,et al.  Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. , 2004, Gynecologic oncology.